302949-02-6

Basic information

• Product Name: 4-Hydroxy -6-iodoquinoline-3- carboxylic acid
• Synonyms: 6-iodo-4-oxo-1H-quinoline-3-carboxylic acid
• CAS NO: 302949-02-6
• Molecular Formula: C10H6INO3
• Molecular Weight: 315.06
• Mol File: 302949-02-6.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 430.9±45.0 °C(Predicted)
• Appearance: /
• Density: 2.040±0.06 g/cm3(Predicted)
• PKA: 6.44±0.10(Predicted)
• CAS DataBase Reference: 4-Hydroxy -6-iodoquinoline-3- carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxy -6-iodoquinoline-3- carboxylic acid(302949-02-6)
• EPA Substance Registry System: 4-Hydroxy -6-iodoquinoline-3- carboxylic acid(302949-02-6)

Safety Data

• Hazardous Substances Data: 302949-02-6(Hazardous Substances Data)

Usage

General Description

4-Hydroxy-6-iodoquinoline-3-carboxylic acid is a chemical compound with potentially important pharmaceutical properties. It is a derivative of quinolinone and contains a hydroxy and carboxylic acid functional group along with an iodine atom. 4-Hydroxy -6-iodoquinoline-3- carboxylic acid has shown to have antimicrobial and antiparasitic activities, making it a potential candidate for the development of new drugs for the treatment of bacterial and parasitic infections. Additionally, 4-Hydroxy-6-iodoquinoline-3-carboxylic acid has also been studied for its potential as an anti-inflammatory and anticancer agent. Researchers continue to explore its therapeutic potential in various medicinal applications.

Upstream product

• 228728-23-2 ethyl 4-hydroxy-6-iodo-3-quinolinecarboxylate 
• 540-37-4 p-aminoiodobenzene 
• 228728-23-2 ethyl 1,4-dihydro-6-iodo-4-oxoquinoline-3-carboxylate 
• 40107-05-9 ethyl α-carbethoxy-β-p-iodoanilinoacrylate 

Downstream Products

• 342617-07-6 4-hydroxyl-6-iodoquinoline 
• 807325-73-1 C₁₇H₁₄IN₃O₂ 

Relevant articles and documents

Repurposing human PDE4 inhibitors for neglected tropical diseases. evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of pdeb1 of trypanosoma brucei

Cyclic nucleotide phosphodiesterases (PDEs) have been identified as important enzyme targets for drug development in both humans and Trypanosoma brucei, the causative agent of human African trypanosomiasis. With this in mind, we recently reported the prof

IMAGING AGENTS

The invention relates to compounds of formula (I), or a salt or solvate thereof which comprise a detectable label. The compounds have use as radioligands for the GABAA receptor.

Controlled derivatization of polyhalogenated quinolines utilizing selective cross-coupling reactions

Straightforward procedures for the derivatization of tri- and tetrahalogenated quinolines utilizing sequential selective Pd-catalyzed cross-coupling reactions are described. Taking advantage of intrinsic halide reactivity, substrate control, and appropria